Indian pharmaceutical stocks, including Lupin, Shilpa Medicare, and Natco Pharma, are under scrutiny following recent USFDA inspections at their manufacturing sites. These audits yielded regulatory observations, prompting companies to address the findings. Alkem Laboratories, however, reported no critical issues from a separate Armenian health ministry audit at its Sikkim facility. Source link India News 2 CPI(M) workers get 20 years in… IIT Kharagpur unveils ‘Impact… Mekedatu dam project: a… Centre Informs Supreme Court Of… Stock Market INR ends slightly lower; Negative… Polymarket Just Got CFTC Sign-Off…. Venture Global Signs 20-Year LNG… Asia-Pacific markets track Wall… Space News Blue Ghost…